GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.
UK pharmaceutical group GSK is in
talks to buy cancer drugmaker Nuvalent for more than $9
billion, the Financial Times reported on Monday, citing people
familiar with the matter.Here are some details:* The companies were locked in discussions late on Monday,
aiming to agree on a deal as soon as this week, the report said.* A potential deal could value Nuvalent between $9 billion
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK to buy US lung cancer drug specialist Nuvalent for £8bn
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars
GSK rachète Nuvalent pour plus de 10 milliards de dollars
Nuvalent: GSK übernimmt Krebsspezialisten für 10,6 Milliarden Dollar
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and…
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma…
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. |…
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
The acquisition is thought to be GSK’s biggest deal in more than a decade.
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
